JNJ

Novartis Sues Janssen Over False Advertisements for Psoriasis Drug
Novartis Sues Janssen Over False Advertisements for Psoriasis Drug
RAPS.org
Novartis
Janssen
JNJ
psoriasis
false advertising
Tremfya
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs
Yahoo/Benzinga
IPOs
biotech
JNJ
Janssen
esketamine
Shockwave Medical
earnings
Sensen Bio
MyoKardia
Flag link:
Johnson & Johnson keeps the heat on Tremfya's rivals with at-home injector nod
Johnson & Johnson keeps the heat on Tremfya's rivals with at-home injector nod
Fierce Pharma
JNJ
Janssen
Tremfya
psoriasis
Novartis
Cosentyx
Eli Lilly
Taltz
Flag link:
J&J bags option on AdoRx lung cancer drugs
J&J bags option on AdoRx lung cancer drugs
Fierce Biotech
JNJ
AdoRx
lung cancer
drug development
Flag link:
Trial Lawyers Are Paying Millions To A Handful Of Experts Necessary To Push Their Talc Cases
Trial Lawyers Are Paying Millions To A Handful Of Experts Necessary To Push Their Talc Cases
Forbes
JNJ
legal
Flag link:
J&J Earns Spot in Fortune’s Top 50 Most Respected Companies
J&J Earns Spot in Fortune’s Top 50 Most Respected Companies
BioSpace
JNJ
Fortune
Flag link:
The fighter, the saint, and the odd man out: the executives who will defend pharma before Congress
The fighter, the saint, and the odd man out: the executives who will defend pharma before Congress
Stat
drug pricing
US Congress
Donald Trump
Richard Gonzalez
AbbVie
Ken Frazier
Merck
JNJ
Jennifer Taubert
Olivier Brandicourt
Sanofi
Pascal Soriot
AstraZeneca
Giovanni Caforio
Bristol-Myers Squibb
Albert Bourla
Pfizer
Flag link:
J&J Hit With Federal Subpoenas Over Baby Powder Contamination Allegations
J&J Hit With Federal Subpoenas Over Baby Powder Contamination Allegations
BioSpace
JNJ
Flag link:
Morphic bags J&J as second big pharma partner for oral integrins
Morphic bags J&J as second big pharma partner for oral integrins
Fierce Biotech
JNJ
AbbVie
Morphic Therapeutic
small-molecule integrins
Flag link:
Pfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets: report
Pfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets: report
Fierce Pharma
M&A
oncology
neurology
Rare Diseases
Pfizer
Merck
JNJ
Biogen
Biomarin
Flag link:
The psychiatry field is buzzing with anticipation — and hesitation — about esketamine for depression
The psychiatry field is buzzing with anticipation — and hesitation — about esketamine for depression
Stat
major depression
esketamine
JNJ
FDA
psychiatrists
Flag link:
Auris acquisition could prompt more mega VC rounds
Auris acquisition could prompt more mega VC rounds
EP Vantage
venture capital
JNJ
Auris Health
devices
Flag link:
Johnson & Johnson CEO on Apple Watch collaboration: 'Ultimately, we're going to save lives'
Johnson & Johnson CEO on Apple Watch collaboration: 'Ultimately, we're going to save lives'
CNBC
JNJ
Apple
Apple Watch
heart arrhythmias
devices
Flag link:
Bayer stresses drug's tolerability in bid for prostate cancer market
Bayer stresses drug's tolerability in bid for prostate cancer market
Yahoo/Reuters
Bayer
prostate cancer
darolutamide
Pfizer
JNJ
Flag link:
Did Johnson & Johnson Just Spit in Alphabet's Face?
Did Johnson & Johnson Just Spit in Alphabet's Face?
Motley Fool
JNJ
Alphabet
Auris Health
robotic surgery
M&A
Verb Surgical
Flag link:
J&J to enter the robotic surgery market with $3.4B Auris Health buy
J&J to enter the robotic surgery market with $3.4B Auris Health buy
Mass Device
JNJ
robotic surgery
Ethicon
M&A
Auris Health
Flag link:
FDA experts offer a big thumbs up for J&J’s flawed application to market esketamine for major depression — but trial failures, safety questions spur concerns
FDA experts offer a big thumbs up for J&J’s flawed application to market esketamine for major depression — but trial failures, safety questions spur concerns
Endpoints
JNJ
FDA
advisory panels
esketamine
major depression
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
Yahoo/Benzinga
Motif Biosciences
Iclaprim
Merck
Keytruda
melanoma
JNJ
esketamine
ASCO
Pfizer
Veru. earnings
Aveo Pharmaceuticals
Calithera Biosciences
Flag link:
Approving J&J's new depression drug would be an unusual move for the FDA
Approving J&J's new depression drug would be an unusual move for the FDA
BioPharma Dive
JNJ
esketamine
FDA
advisory panels
Flag link:
J&J’s Esketamine for Depression Faces an FDA Panel Next Week
J&J’s Esketamine for Depression Faces an FDA Panel Next Week
BioSpace
JNJ
FDA
esketamine
major depression
Flag link:

Pages